Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from CellSource Co., Ltd. ( (JP:4880) ).
CellSource Co., Ltd. reported its consolidated financial results for the three months ending January 31, 2025, indicating net sales of 849 million yen but an operating loss of 62 million yen. This marks the company’s transition to consolidated accounting, which does not allow for year-on-year comparisons. The company maintains a strong equity-to-asset ratio of 85.0%, reflecting a robust financial position despite the quarterly loss. The forecast for the fiscal year ending October 31, 2025, anticipates a return to profitability with projected net sales of 4,501 million yen and a profit attributable to owners of 255 million yen.
More about CellSource Co., Ltd.
CellSource Co., Ltd. operates in the biotechnology industry, focusing on regenerative medicine and cell therapy. The company is listed on the Tokyo Stock Exchange and is known for its innovative approaches in cell processing and therapy solutions.
YTD Price Performance: -2.64%
Average Trading Volume: 92,660
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen16.05B
Learn more about 4880 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue